These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 20580798)

  • 1. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.
    Galmarini CM; Warren G; Senanayake MT; Vinogradov SV
    Int J Pharm; 2010 Aug; 395(1-2):281-9. PubMed ID: 20580798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines.
    Galmarini CM; Warren G; Kohli E; Zeman A; Mitin A; Vinogradov SV
    Mol Cancer Ther; 2008 Oct; 7(10):3373-80. PubMed ID: 18852140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates.
    Senanayake TH; Warren G; Wei X; Vinogradov SV
    J Control Release; 2013 Apr; 167(2):200-9. PubMed ID: 23385032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel anticancer polymeric conjugates of activated nucleoside analogues.
    Senanayake TH; Warren G; Vinogradov SV
    Bioconjug Chem; 2011 Oct; 22(10):1983-93. PubMed ID: 21863885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of nanogel drug carriers and their formulations with nucleoside 5'-triphosphates.
    Vinogradov SV; Kohli E; Zeman AD
    Pharm Res; 2006 May; 23(5):920-30. PubMed ID: 16715382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
    Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
    Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acid-Triggered Release of Native Gemcitabine Conjugated in Polyketal Nanoparticles for Enhanced Anticancer Therapy.
    Zhong H; Mu J; Du Y; Xu Z; Xu Y; Yu N; Zhang S; Guo S
    Biomacromolecules; 2020 Feb; 21(2):803-814. PubMed ID: 31995366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
    Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
    Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
    Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
    Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.
    Reddy LH; Dubernet C; Mouelhi SL; Marque PE; Desmaele D; Couvreur P
    J Control Release; 2007 Dec; 124(1-2):20-7. PubMed ID: 17878060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
    Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach.
    Hung SW; Marrache S; Cummins S; Bhutia YD; Mody H; Hooks SB; Dhar S; Govindarajan R
    Cancer Lett; 2015 Apr; 359(2):233-40. PubMed ID: 25600708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro assessment of nucleoside analogs in multiple myeloma.
    Krett NL; Ayres M; Nabhan C; Ma C; Nowak B; Nawrocki S; Rosen ST; Gandhi V
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):113-21. PubMed ID: 15133625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic.
    Papa AL; Sidiqui A; Balasubramanian SU; Sarangi S; Luchette M; Sengupta S; Harfouche R
    Cell Oncol (Dordr); 2013 Dec; 36(6):449-57. PubMed ID: 24081907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
    Wang F; Zhang Z
    Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Non-clinical studies of gemcitabine--the mode of action and antitumor activities].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1999 Feb; 26(3):393-400. PubMed ID: 10065109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.
    Wonganan P; Lansakara-P DS; Zhu S; Holzer M; Sandoval MA; Warthaka M; Cui Z
    J Control Release; 2013 Jul; 169(1-2):17-27. PubMed ID: 23570983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia.
    Kim DH; Guo Y; Zhang Z; Procissi D; Nicolai J; Omary RA; Larson AC
    Adv Healthc Mater; 2014 May; 3(5):714-24. PubMed ID: 24574255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
    Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
    Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.